Evidence map›Paper›PMID 24551259›Full record

ArticlePLoS neglected tropical diseases2014

A monoallelic deletion of the TcCRT gene increases the attenuation of a cultured Trypanosoma cruzi strain, protecting against an in vivo virulent challenge.

Fernando J Sánchez-Valdéz, Cecilia Pérez Brandán, Galia Ramírez, Alejandro D Uncos, M Paola Zago, Rubén O Cimino, Rubén M Cardozo, Jorge D Marco, Arturo Ferreira, Miguel Ángel Basombrío

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. The many faces of parasite calreticulin.Frontiers in immunology · 2023
    Review
  6. The Kinetoplastid-Specific Protein TcCAL1 Plays Different Roles DuringFrontiers in cellular and infection microbiology · 2022
    Article
  7. Is It Possible to Intervene in the Capacity ofFrontiers in immunology · 2021
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Frontiers in microbiology · 2017
    Review
  15. Article
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Fernando J Sánchez-ValdézInstituto de Patología Experimental-CONICET, Universidad Nacional de Salta, Salta, Argentina.
Cecilia Pérez BrandánInstituto de Patología Experimental-CONICET, Universidad Nacional de Salta, Salta, Argentina.
Galia RamírezDepartamento de Medicina Preventiva Animal, Facultad de Ciencias Veterinarias y Pecuarias, Universidad de Chile, Santiago, Chile.
Alejandro D UncosInstituto de Patología Experimental-CONICET, Universidad Nacional de Salta, Salta, Argentina.
M Paola ZagoInstituto de Patología Experimental-CONICET, Universidad Nacional de Salta, Salta, Argentina.
Rubén O CiminoCátedra de Química Biológica, Universidad Nacional de Salta, Salta, Argentina.
Rubén M CardozoInstituto de Patología Experimental-CONICET, Universidad Nacional de Salta, Salta, Argentina.
Jorge D MarcoInstituto de Patología Experimental-CONICET, Universidad Nacional de Salta, Salta, Argentina.
Arturo FerreiraPrograma Disciplinario de Inmunología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Miguel Ángel BasombríoInstituto de Patología Experimental-CONICET, Universidad Nacional de Salta, Salta, Argentina.
National University of Salta · ARConsejo Nacional de Investigaciones Científicas y Técnicas · ARUniversity of Chile · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trypanosoma cruzi calreticulin (TcCRT) is a virulence factor that binds complement C1, thus inhibiting the activation of the classical complement pathway and generating pro-phagocytic signals that increase parasite infectivity. In a previous work, we characterized a clonal cell line lacking one TcCRT allele (TcCRT+/-) and another overexpressing it (TcCRT+), both derived from the attenuated TCC T. cruzi strain. The TcCRT+/- mutant was highly susceptible to killing by the complement machinery and presented a remarkable reduced propagation and differentiation rate both in vitro and in vivo. In this report, we have extended these studies to assess, in a mouse model of disease, the virulence, immunogenicity and safety of the mutant as an experimental vaccine. Balb/c mice were inoculated with TcCRT+/- parasites and followed-up during a 6-month period. Mutant parasites were not detected by sensitive techniques, even after mice immune suppression. Total anti-T. cruzi IgG levels were undetectable in TcCRT+/- inoculated mice and the genetic alteration was stable after long-term infection and it did not revert back to wild type form. Most importantly, immunization with TcCRT+/- parasites induces a highly protective response after challenge with a virulent T. cruzi strain, as evidenced by lower parasite density, mortality, spleen index and tissue inflammatory response. TcCRT+/- clones are restricted in two important properties conferred by TcCRT and indirectly by C1q: their ability to evade the host immune response and their virulence. Therefore, deletion of one copy of the TcCRT gene in the attenuated TCC strain generated a safe and irreversibly gene-deleted live attenuated parasite with high immunoprotective properties. Our results also contribute to endorse the important role of TcCRT as a T. cruzi virulence factor.

Indexed as

AnimalsCalreticulinGene DeletionHost-Parasite InteractionsMaleMice, Inbred BALB CMice, NudeProtozoan ProteinsTrypanosoma cruziVirulenceCalreticulinProtozoan Proteins

Identifiers

PMID24551259
PMCPMC3923724
OpenAlexW2022873560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.